A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND XXXXX) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL).

Trial Profile

A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND XXXXX) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Epratuzumab (Primary) ; Rituximab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Pooled retrospective analysis (n=174) of this trial and two other trials (see NCT00117975 and NCT01145495) evaulating effects of early progression of disease was presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 08 Dec 2015 Pooled exploratory analysis (n=241) of 5 studies including data from this study and 4 other trials (see CTP 700006652, 700009482, 700057042, 70059082) were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Aug 2013 Status changed from active, no longer recruiting to completed, according to an Immunomedics media release reporting final results were published online in the journal Cancer on 6 Aug 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top